Literature DB >> 17947339

Transcriptional properties of feline p53 and its tumour-associated mutants: a yeast-based approach.

Umberto Cardellino1, Yari Ciribilli, Virginia Andreotti, Paola Modesto, Paola Menichini, Gilberto Fronza, Claudio Pellegrino, Alberto Inga.   

Abstract

Mutations at the tumour suppressor gene TP53 are associated with nearly half of human cancers, but they appear to be rare ( approximately 10%) in feline neoplasms. The reasons for this difference are presently unclear but might be related to evolutionary divergence of p53 functions. To begin exploring this issue, we developed a yeast-based functional assay to measure the transcriptional ability of wild-type (wt) or mutant feline p53 (fe_p53) in comparison with human or murine p53 (hu_p53, mo_p53). fe_p53 cDNA was cloned and expressed in a panel of yeast reporter strains engineered to contain the ADE2 or the luciferase gene under p53 control via different p53 response elements. We established that wt fe_, hu_ and mo_p53 can act as transcription factors in yeast with overlapping DNA sequence specificities. Random mutagenesis and phenotypic evaluation of fe_ and hu_p53 cDNAs was also performed, revealing equal susceptibility to deleterious mutations. Five tumour-associated fe_p53 mutants exhibited a similar impact on the transactivation capacity (partial or complete loss) compared to the corresponding hu_p53 mutants. Given the high conservation of the intrinsic functional properties of fe_p53, further studies will be needed to clarify the role of p53 in feline carcinogenetic pathways.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17947339     DOI: 10.1093/mutage/gem038

Source DB:  PubMed          Journal:  Mutagenesis        ISSN: 0267-8357            Impact factor:   3.000


  1 in total

1.  Gene expression association study in feline mammary carcinomas.

Authors:  Daniela Ferreira; Bárbara Martins; Maria Soares; Jorge Correia; Filomena Adega; Fernando Ferreira; Raquel Chaves
Journal:  PLoS One       Date:  2019-08-28       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.